<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Paper And Industrial essayImportant</title>
	<atom:link href="http://www.perilip.org/tag/important/feed" rel="self" type="application/rss+xml" />
	<link>http://www.perilip.org</link>
	<description>About  paper and industrial essay Share ideas</description>
	<lastBuildDate>Sat, 09 Jan 2010 19:11:24 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Important Issues in Pharmaceutical Industry</title>
		<link>http://www.perilip.org/important-issues-in-pharmaceutical-industry</link>
		<comments>http://www.perilip.org/important-issues-in-pharmaceutical-industry#comments</comments>
		<pubDate>Wed, 02 Dec 2009 11:31:23 +0000</pubDate>
		<dc:creator></dc:creator>
				<category><![CDATA[Articles]]></category>
		<category><![CDATA[Important]]></category>
		<category><![CDATA[Industry]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Pharmaceutical]]></category>

		<guid isPermaLink="false">http://www.perilip.org/important-issues-in-pharmaceutical-industry</guid>
		<description><![CDATA[<p>Many of the strongest European pharmaceutical firms adopted this strategy, seeking to develop their own capabilities across a relatively narrow front while working with biotech startups. The small, university-linked biotechs were at first almost entirely an American phenomenon, and this gave the large U.S. pharmaceutical companies an initial advantage, as did the federal government&#8217;s support for basic research in molecular genetics. But soon, European governments were attempting to close the widening biotech gap, hoping that government support would make up for the venture capital <a href='http://www.perilip.org/important-issues-in-pharmaceutical-industry' rel="nofollow">Read more</a></p>Here is no comments yet by the time your rss reader get this, Do you want to be the first commentor? Hurry up]]></description>
			<content:encoded><![CDATA[<p>Many of the strongest European pharmaceutical firms adopted this strategy, seeking to develop their own capabilities across a relatively narrow front while working with biotech startups. The small, university-linked biotechs were at first almost entirely an American phenomenon, and this gave the large U.S. pharmaceutical companies an initial advantage, as did the federal government&#8217;s support for basic research in molecular genetics. But soon, European governments were attempting to close the widening biotech gap, hoping that government support would make up for the venture capital <a href='http://www.perilip.org/important-issues-in-pharmaceutical-industry' rel="nofollow">Read more</a></p>Here is no comments yet by the time  your rss reader get this, Do you want to be the first commentor? Hurry up ]]></content:encoded>
			<wfw:commentRss>http://www.perilip.org/important-issues-in-pharmaceutical-industry/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

